Comparative effects of metformin and pioglitazone on YKL-40 in type 2 diabetes: a randomized clinical trial
Conclusions
Metformin is more effective in reduction of YKL-40 concentration in short term and the effect seems to be independent of degree of glycemic control, or hsCRP reduction.
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research
More News: Actos | Cholesterol | Clinical Trials | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Metformin | Statistics